**Pre-conceptional maternal vitamin B12 supplementation improves offspring**

**neurodevelopment at 2 years of age: PRIYA trial**

**Type of manuscript: Brief Research Report**

Naomi D'souza1†, Rishikesh V Behere1†, Bindu Patni2, Madhavi Deshpande2, Dattatray Bhat1, Aboli Bhalerao1, Swapnali Sonawane1, Rohan Shah1, Rasika Ladkat1, Pallavi Yajnik1, Souvik K Bandyopadhyay3, Kumaran K4, Caroline Fall4, Chittaranjan S Yajnik1\*.

1 - Diabetes Unit, KEM Hospital Research Center, Pune, India

2 - TDH Rehabilitation and Morris Child Development Centre at KEM Hospital, Pune

3-Strategic Consulting, Cytel Inc, Cambridge, Massachusetts, USA

4 - MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom

† The authors have contributed equally to this work and share first authorship

**\* Corresponding author**

Dr Chittaranjan S Yajnik

Director, Diabetes Unit

KEM Hospital Research Center

489, Rasta Peth

Pune – 411011, India

Email: csyajnik@gmail.com

Ph: +919822847481

Number of Pages: 17

Word count: 4416

Number of Tables: 2

Number of figures: 2

**Abstract**

**Background:** The first thousand days window does not include the pre-conceptional period. Maternal pre-conceptional health has a profound influence on early embryonic development (implantation, gastrulation, placentation etc). Nutrition provided by B-complex vitamins is important for fetal growth, especially neural development. We report effects of a maternal pre-conceptional vitamin B12 and multi micronutrient (MMN) supplementation on offspring neurodevelopmental performance.

**Methods:** In the Pune Rural Intervention in Young Adolescents trial (PRIYA), adolescents (N=557, 226 females) were provided with vitamin B12 (2μg/day) with or without multiple micronutrients, or a placebo, from preconception until delivery. All groups received mandatory iron and folic acid. We used the Bayley’s Scale of Infant Development (BSID-III) at 24-42 months of age to investigate effects on offspring neurodevelopment.

**Results:** Participants had similar baseline B12 levels. The levels improved in the B12 supplemented groups during pre-conception and pregnancy (28 weeks gestation), and were reflected in higher cord blood holotranscobalamin (holo-TC) levels compared to the placebo group. Neurodevelopmental outcomes in the B12 alone group (n=21) were better than the placebo (n=27) in cognition (p=0.044) and language (p=0.020) domains (adjusted for maternal baseline B12 levels). There was no difference in neurodevelopmental outcomes between the B12+MMN (n=26) and placebo group. Cord blood Brain Derived Neurotrophic Factor (BDNF) levels were highest in the B12 alone group, though not significant.

**Conclusion:** Pre-conceptional vitamin B12 supplementation improved maternal B12 status and offspring neurodevelopment at 2 years of age. The usefulness of cord BDNF as a marker of brain development needs further investigation. Our results highlight the importance of intervening during pre-conception.

**Key words:** Vitamin B12, pre-conceptional supplementation, neurodevelopmental improvement in offspring

**1.0 Introduction**

The developing fetus is dependent on its mother for its nutrition. Maternal nutrition before and during pregnancy affects fetal growth and development, and maternal malnutrition may predispose the offspring to undesirable outcomes in later life. This concept is called ‘fetal programming’. This is the backbone for the Developmental Origins of Health and Disease (DOHaD) paradigm which expanded the idea to include ‘health’ as a programmed state (1,2). Pregnancy and the first two years of life (1000 days) are considered the most crucial window for programming (3).

Maternal nutritional factors (both macro and micronutrients) influence neurodevelopmental processes *in utero*, such as neurogenesis, myelination, synaptogenesis, and cortical brain growth (3).Vitamins B12 and folate are of special interest due to their role in the one carbon metabolism pathway. This represents a series of biochemical reactions involving the methionine and folate cycles.  The methylation of homocysteine involves the transfer of a methyl group from 5-methyl tetra-hydro folate (THF) by methionine synthase (MS). Vitamin B12 is a cofactor for this reaction. This transfer in turn generates S-adenosyl methionine (SAM) which is a universal methyl donor. One carbon metabolism supports important cellular processes such as DNA synthesis, repair, and methylation, which is important for epigenetic regulation of gene expression (4). Offspring of mothers with low maternal vitamin B12 and folate status during pregnancy have a higher risk of neural tube defects and neurodevelopmental disorders (Autism, Attention Deficit Hyperactivity Disorder (ADHD)), poorer cognitive development, and smaller brain volumes in childhood (5–8). In animal models (rats), offspring of mothers exposed to a high folate and low vitamin B12 diet show lower levels of Brain Derived Neurotrophic Factor (BDNF) in the brain, and poorer cognitive function (9,10).

In India, vitamin B12 deficiency is widely prevalent in pregnant women (50-70%) (11,12) and is attributable to the socio-cultural practice of vegetarianism and poor economic status (13–16). This deficiency is associated with a range of adverse pregnancy and offspring health outcomes (17). In prospective birth cohorts from western India, we have earlier shown that exposure to low maternal vitamin B12 *in utero* is associated with poorer cognitive functioning at the age of 2 and 9 years in the offspring (18,19). However, public health policy in India mandates only iron and folic acid supplementation to women in the reproductive age group, and during pregnancy and lactation. A randomized controlled trial in South India showed that supplementing 50 μg/day oral B12 from 14 weeks of pregnancy until 6 weeks postpartum improved B12 concentrations in breast milk, the vitamin B12 status of infants at 6 weeks and infant cognitive function at 30 months of age (20,21).

Important milestones in fetal neural development such as neural tube closure are completed by 26-28 days of gestation (22). The majority of pregnancies in India are unplanned, and by the time pregnancy is detected (typically between 10-14 weeks gestation) this early developmental window is lost. Pre-conceptional supplementation will ensure that the mother has improved vitamin stores during the early neurodevelopmental period. The success of pre-conceptional folic acid supplementation in preventing neural tube defects is well known (23–25). Few studies have examined the effects of pre-conceptional maternal micronutrient supplementation on offspring neurodevelopment in India. This approach will expand the 1000 days concept to include the pre-conceptional period.

The Pune Rural Intervention in Young Adolescents (PRIYA) is a pre-conceptional vitamin B12 and multi micronutrient supplementation trial in adolescent participants of the Pune Maternal Nutrition Study. Here we report neurodevelopmental outcomes at 2 years of age in the offspring of female participants in the trial. We hypothesised that pre-conceptional B12 supplementation in the mothers would contribute to better neurodevelopmental outcomes in their offspring.

**2.0 Material and Methods**

2.1*PRIYA trial*

The PRIYA trial methods have been published previously (26). Briefly, The Pune Maternal Nutrition Study (PMNS) is a pre-conceptional observational birth cohort set up in 1993 (Figure 1). Married non-pregnant women were recruited from six villages around Pune and those who became pregnant were followed up. Seven hundred and sixty-two children were born and followed up serially. At ~17 years of age, 690 participants from the PMNS cohort (11) were screened for inclusion in the PRIYA trial. Of these, 117 were excluded due to severe vitamin B12 deficiency (<100 pmol/L) because of the ethical imperative of a placebo-controlled trial. Sixteen were excluded due to systemic illnesses. Five hundred and fifty-seven (266 females) participants were randomized (Figure 1) to receive either a placebo, B12 (2μg/day) + multiple micronutrients (MMN) or B12 alone (2μg/day). The composition of the MMN tablet (Supplementary Table 4) was guided by the WHO/UNICEF/UNU international multiple micronutrient preparation (UNIMMAP). We excluded Iron and Folic Acid because the mandated IFA tablets (Iron and Folic Acid) were given to all participants as per Government of India recommendations (100 mg elemental Iron and 500 μg folic acid once a week during adolescence, and at least 100 tablets during pregnancy). The investigational supplements (vitamin B12 containing) were continued for the female participants daily until their first delivery. They and the study team were blinded to the vitamin/micronutrient supplementation.

This paper describes the findings in the female participants and their children. Participants were followed up regularly for health problems, and marriages were recorded. Married women were monitored to detect pregnancy which was confirmed by a urine pregnancy test. At 24-28 weeks gestation, mothers visited the Diabetes Unit, KEM Hospital Research Center Pune, for a fasting oral glucose tolerance test (as per international guidelines) and clinical and biochemical evaluations. The clinical evaluation included anthropometric measurements, an obstetric consultation and estimate of foetal growth by ultra-sonography. We also obtained socio demographic information (assessed using the Standard of Living Index questionnaire from the National Family Health Survey of India (NFHS).

Details of deliveries were recorded (gestational age and type of delivery). Cord blood samples were collected and processed for hematological and nutrient measurements. We performed detailed anthropometric measurements on the baby within 72 hours of birth.

We measured circulating concentrations of vitamins B12, holotranscobalamin (holo-TC), folate, and total homocysteine at baseline, 6-12 months after the start of the supplementation (at ~18 years of age), 28 weeks gestation, and in cord blood (Table 1). We additionally measured B2 and B6 levels in mothers at 28 weeks gestation and in offspring cord blood.

Hemogram was measured on a Beckman Coulter analyzer (AC.T diffTM Analyzer, Florida, USA) on the day of the collection. Plasma vitamin B12 and folate were measured using a microbiological assay and total homocysteine, vitamin B2 and B6 by HPLC (PerkinElmer 200 Series, PerkinElmer, Shelton, CT, USA. Plasma holo-TC was measured by a two-step immunoassay using CMIA technology (Architect, Abbott GmbH & Co. KG, Germany). This represents the fraction of vitamin B12 transported on transcobalamin-II and is available for the peripheral tissues, hence also called ‘active’ vitamin B12. It is increasingly used as a more sensitive marker for B12 deficiency. The remaining vitamin B12 (70-80%) is attached to haptocorrin and is not available for peripheral tissues. Total vitamin B12 (called vitamin B12) is the sum of the two. Plasma BDNF was measured in cord blood using ELISA kit (XpressBio, Frederick, USA).

2.2 *Neurodevelopmental assessments*

The offspring born in the trial were followed up every 6 months until 2 years of age for measurements of their growth. Once they reached 24 months of age, the parents were approached regarding participation in the neurodevelopment study, and their written informed consent was obtained. The neurodevelopmental assessment was performed at the Child Development Center (TDH center), KEM Hospital, Pune.

The neurodevelopmental assessment was performed using the Bayley’s Scale of Infant Development (BSID-III) (27). The BSID-III assesses the developmental status of infants from 1 to 42 months of age. The scales assess five domains across three main subscales: 1) cognitive 2) language - receptive and expressive language and 3) motor - which assesses [gross](https://en.wikipedia.org/wiki/Gross_motor_skill) and [fine motor skills](https://en.wikipedia.org/wiki/Fine_motor_skill).  The assessment was performed by trained clinical psychologists certified to perform the BSID-III. Testing was carried out in a quiet room, with a parent or guardian present, and instructions were provided in a language that was comfortable for the child. All children were assessed between 24 and 42 months of age. Each test protocol was independently reviewed and scored by two raters. The BSID-III test yields raw scores based on the performance of the child on test items for cognitive, expressive, and receptive communication, and fine and gross motor skills. The raw scores were converted into age standardized scaled scores as recommended in the manual. Summation of the scaled scores yields 3 composite scores for the cognitive, language and motor skills domains. We used the composite scores in our analysis. Composite scores were categorized into average, below or above average performance, based on standardized criteria provided in the manual, where the average is 100 with SD of 15 and a score of <85 is considered to be below average (27).

As part of ongoing assessments in the PMNS cohort, maternal intelligence (determined by the mothers’ Intelligence Quotient (IQ) score) was assessed in some of the mothers at age 22~24 years using the Weschler’s Adult Intelligence Scale-IV (WAIS-IV).

2.3 *Ethical considerations*

Details of community participation in the planning of this trial have been described earlier (26). The original PRIYA trial was approved by the KEM Hospital Research Centre Ethics committee and monitored by a Data Safety Monitoring Board (DSMB) and a Scientific Advisory Committee (SAC). The trial was registered with the CTRI (2012/12/003212) and ISRCTN (32921044). Neurodevelopmental follow up of the offspring was approved by the KEM Hospital Research Centre Ethics committee and registered in (clinical trials.gov ID: NCT03088189). Written informed consent was obtained from the parents of the children before conducting the neurodevelopmental assessment.

2.4 *Statistical Analysis*

The purpose of our analysis was to see if pre-conceptional B12 and micronutrient supplementation in the mothers led to improvement in offspring neurodevelopmental performance (composite BSID-III scores) at 2 years of age. We also investigated the effect of supplementation on circulating vitamin levels in the mother and cord blood, and on cord blood BDNF levels.

We first examined whether randomization had equally distributed potential confounders such as parental education and standard of living index, maternal age, IQ, and anthropometry, length of supplementation and compliance across the three supplementation groups.

All data were represented as either mean and standard deviation (for normally distributed variables) or median and 25th-75th percentile (for skewed variables). The skewed outcome variables (maternal and child biochemical measures, birth outcomes and neurodevelopmental measures) were log transformed. We used Pearson’s correlation coefficient to test associations between the length of supplementation and biochemical measures at 28-week gestation and offspring cord blood. We compared differences in outcome variables between B12 alone or B12+MMN groups and the placebo group using the t-test. Adjustments for additional covariates (e.g. maternal B12 levels at screening) were performed using ANCOVA. We also examined longitudinal changes in the logarithmic values of vitamin B12 concentrations between time points and treatment groups using a two-way repeated measures ANOVA. Further, we examined the additional effect of duration of supplementation and compliance in the same model. We used a non-parametric test (Mann-Whitney U test) to test the significance of difference in cord BDNF values between the supplementation groups because BDNF values could not be normalized by various transformations. Statistical analysis was performed using SPSS 25.0 and R statistical software 4.1.1.

**3.0 Results**

Of the 266 women randomized in the trial, 182 were married, 166 became pregnant, and 149 delivered a live baby (Figure 1). Between May 2017 and February 2020, we approached the parents of 85 children who had attained the age of 2 years, for participation in the neurodevelopmental study. We had to halt the assessments after February 2020 due to the COVID-19 pandemic. None of the children had significant neurodevelopmental disorders (cerebral palsy, seizure disorders, or neural tube defects). Seven children who were above the inclusion age of 42 months as per the BSID norms, were excluded from analysis after confirming that they had achieved appropriate neurodevelopment for 42 months of age. Assessment could not be completed in 4 children. Our analysis is based on the remaining 74 children. The median age of the children at the time of performing the BSID was 29 months (Table1). There were 42 boys and 32 girls; of these, 27 were in the placebo group, 26 in the B12+MMN and 21 in the B12 alone group. There were no differences in gestational age at delivery, birth weight, length or head circumference amongst the offspring in the three supplementation groups. Similarly, there were no differences in parental education, standard of living index, maternal age, or IQ. (Table 1)

The children who were not invited for the study because they were below 24 months of age differed from those studied; they had higher socio-economic status and parental education, higher maternal and cord B12 and holo-TC, and lower cord homocysteine compared to the study group. (Supplementary Table 1).

3.1 *Effect of supplementation on maternal and newborn micronutrient status, and birth measures*

At baseline, maternal B12 and holo-TC levels were similar across the three supplementation groups (Table 1). Fifty one percent of the participants had vitamin B12 deficiency at screening (B12<150 pM), and this reduced to 22% at 6-12 months after starting supplementation. There was a rise in vitamin B12 and holo-TC levels in the B12 supplemented groups compared to the placebo group, both pre-conceptionally (18 years of age) and at 28 weeks of gestation. There was no significant association between length of supplementation (from start of supplementation till date of 28 weeks gestation and date of delivery) and circulating concentration of vitamin B12 in either group. There was a significant association between length of supplementation and holo-TC concentrations in the cord blood of the B12 alone group (r=0.462 p= 0.035).

Repeated measures ANOVA showed a significant effect of time (F= 18.517, p <0.001) and treatment (F=9.363, p< 0.001) on log serial B12 concentrations. Addition of length of supplementation and compliance did not change the result. Post hoc comparisons using Bonferroni correction, showed that the log B12 concentrations in both B12+MMN ( 95% CI= 0.14, 0.56, p<0.001) and B12 alone (95% CI= 0.17, 0.63, p<0.001) groups were significantly higher than the placebo group. There was no difference in vitamin B12 concentrations between B12+ MMN and B12 alone groups. Cord blood levels of holo-TC were significantly higher in both the B12 supplemented groups compared to the placebo group, though vitamin B12 levels were similar.

Baseline plasma homocysteine concentrations were high but similar in the three supplementation groups, and fell substantially in the vitamin B12 supplemented groups pre-conceptionally. During pregnancy, as expected, plasma homocysteine concentrations fell in all groups. They were similar in the three groups during pregnancy and in the cord blood.

Circulating folate concentrations were similar at baseline in the three groups and increased during pregnancy (due to supplementation). Folate levels were significantly lower at 28 weeks gestation in the B12+MMN group compared to those in the placebo group. Folate levels were similar in the cord blood across the groups. Circulating B2 levels were higher in the B12+MMN group as compared to the placebo group during 28 weeks gestation.

Hemoglobin concentrations were similar in the mother and the offspring across all the groups.

3.2 *Comparison of BSID scores and cord BDNF between supplementation groups*

Age standardized composite scores for the domains of cognition, motor and language development were obtained on 74 children. There was no difference in performance between males and females (supplementary Table 3). No significant developmental delays were observed in any of the children (score < 69). Few children showed a below average performance on the cognitive (4.1%, n=3), motor (4.2%, n=3), and language domain (8.3%, n=6) (score < 85) (supplementary table 2).

The offspring of mothers in the B12 alone group performed the best in the cognitive and language domains, and significantly better than the placebo group (Table 2). This difference persisted after adjusting for the baseline plasma vitamin B12 concentrations. Cognition and language composite scores were 5 -7% higher in the B12 alone group than the placebo group.

There were no significant differences between the B12+MMN group and the placebo group on any of the neurodevelopmental domains.

The two supplementation groups had higher cord BDNF values than the placebo group, the B12 alone group had the highest values, however the difference was non-significant (Table 1). Cord blood BDNF values did not show significant associations with any of the BSID-III composite scores.

**4.0 Discussion**

In this rural Indian population with a substantial prevalence of B12 deficiency, we found that supplementation of adolescents with 2 μg /day of B12 significantly improved their own B12 status (total B12 and holo-TC) and offspring cord blood holo-TC.  Offspring whose mothers received vitamin B12 alone performed better than offspring of mothers in the placebo group in neurodevelopmental assessments (cognitive and language domain of the BSID-III test at 24-42 months of age). Offspring whose mothers received B12+MMN performed similarly to the placebo group.

The role of pre-conceptional folic acid supplementation in preventing NTDs is well established, especially in western (mainly non-vegetarian) populations (23,24). In vegetarian populations like India, vitamin B12 is likely to play a similar role, because both folate and B12 act as cofactors for the enzyme methionine synthase, in methylation reactions. Studies in India have highlighted an association of both maternal vitamin B12 and folate with different outcomes in the offspring including neurodevelopmental performance. Studies in Pune showed an association of low maternal vitamin B12 status (low holo-TC concentrations and TCN2 polymorphisms) with an increased risk of NTD, and a positive association between maternal vitamin B12 status during pregnancy and offspring neurocognitive performance at 2 and 9 years of age (5,18,19). A study in North Indian children aged 12–18 months found that both vitamin B12 and folate status had significant associations with cognitive performance (28) while a study in Mysore found that higher maternal folate concentrations, but not vitamin B12, during pregnancy were associated with better cognitive ability in children at 9-10 years of age (29). Adequate status of both vitamins is likely to be important for brain development and function. Recent systematic reviews, including both observational and interventional studies, provide a moderate level of evidence for a role of maternal B12 status in determining offspring cognitive function, and highlight a need for more studies from developing countries (17,30). Studies in Mexico and Singapore have also reported an association between maternal dietary intake of vitamin B12 and offspring cognitive abilities (31,32). Observations in the ALSPAC cohort in the UK suggests a weak association of a maternal genetic determinant of circulating vitamin B12 concentrations (*FUT*2) and offspring IQ at 8 years of age (33). On the other hand, a cohort study in Canada showed no significant associations between maternal vitamin B12 concentrations and BSID-III outcomes in their offspring at 18 months (32). This may be due to a lack of significant variation in maternal vitamin B12 status, given the low prevalence of vitamin B12 deficiency in their population (34).

Our findings from this pre-conceptional maternal micronutrient supplementation trial fills an important gap in the literature. Our observations are supported by a maternal B12 supplementation study from south India, which supplemented mothers with 50 μg vitamin B12 from the 1st trimester of pregnancy until 6 weeks postpartum. Supplementation improved maternal B12 levels in the third trimester (20) and offspring had better neurodevelopmental scores (language domain) at 30 months of age (21). In another trial, vitamin B12 (1.8 μg) and/or folic acid (150 μg) supplementation in 6–30-month-old children for a period of 6 months showed improvement in their neurocognitive performance (35). In this study B12 alone group showed improvement in gross motor functioning and the B12 + folic acid group in gross motor as well as problem-solving functioning compared to the placebo; folic acid alone had no effect

A high prevalence of B12 deficiency is unique to the Indian context due to the socio-cultural practice of vegetarianism. In a previously published systematic review (17), we found a high prevalence of B12 deficiency during pregnancy reported from southern (51%), western and northern India (70-74%). Severe absorption defects (i.e. pernicious anaemia) are rare and vitamin B12 deficiency is largely a low dietary intake problem (15–18). This offers a unique opportunity to control a modifiable risk factor at the public health scale to improve neurodevelopment and human capital in the next generation. The utility of this approach in populations with a high consumption of fish and meat (e.g. in coastal areas of India) will need to be examined, keeping in mind that folate may be more important than B12 in these populations. Our choice of a near- recommended dietary allowance (RDA) dose of B12 (2 μg/day) was based on our earlier studies showing adequate absorption of oral B-12 (36) in this population and the demonstration in a pilot study of improvement in B-12 and homocysteine status after oral supplementation with 2 or 10 μg/day for 1 year (37). In another study of severely B12 deficient girls, (plasma B12 <100 pmol/l) we demonstrated an improvement in haematological parameters and peripheral and autonomic nerve functions after supplementing 2 μg/day of vitamin B12 for 11 months (38). In the present study we found a rise in both total B12 and holo-TC levels in the supplemented groups within a few months of starting supplementation at 28 weeks gestation, and in the cord blood. Use of a small dose of vitamin B12 makes our results important for public health actions. Thus, we believe that our current study fills an important gap to help public health policy to include supplementation with a physiological dose of vitamin B12 among adolescents and reproductive age women. This may improve not only their own health, but that of the next generation’s as well. Being aware of the difficulties of achieving long term compliance with tablet supplementation in relatively asymptomatic individuals, we have recently reported the efficacy of commonly eaten vitamin fortified food items (a nutrient bar and yogurt) to achieve better vitamin B12 status (39). All these approaches are usable in the national programmes to improve micronutrient nutrition of children, adolescents and pregnant mothers. The improved cognitive outcomes were seen specifically in the B12 alone supplemented group and not in the B12+MMN group. We are unsure about the reasons for this. Though the circulating levels of vitamin B12, holo-TC, and BDNF appeared higher in the B12 alone group, the difference from the B12+MMN group was not significant. There was no difference in the compliance and length of supplementation in different groups. Maternal IQ, parental education, and socio-economic status which may influence child neurodevelopment were also similar. It has been postulated that administration of a combination of multiple micro nutrients may interfere with actions of each other (40), such a mechanism could operate in the B12+MMN group. It is notable that the effects of maternal multiple micronutrient supplementation on offspring outcomes are inconsistent. A systematic review from 9 trials (6 of which used the UNIMMAP micronutrient formulation) did not find favourable effects on child mortality, birth size, or offspring cognition (41).

Vitamins B12 and folate participate in the one-carbon metabolism pathway to stimulate synthesis of precursor nucleotides for DNA synthesis, and also generate the universal methyl donor S-Adenosyl methionine (SAM) which is involved in methylation of DNA (an important epigenetic mechanism), proteins and lipids and generating neurotransmitters (42,43). These mechanisms are reputedly involved in fetal growth and differentiation and a deficiency or imbalance of these vitamins may result in a permanent change in the structure and function of developing tissues which may manifest as disorders in later life (‘fetal programming’) (1). We have demonstrated alterations in adiposity and insulin resistance in children whose mothers had an imbalance of these vitamins (low B12 – high folate) during pregnancy (11). Animal studies have shown differences in the expression of neurotrophic factors such as BDNF in the brains of fetuses whose mothers were exposed to low vitamin B12 status (9). In our study, though we did not find significant differences in cord blood BDNF concentrations between supplementation groups, the values tended to be higher in the B12 alone group. Further studies are required to understand the utility of cord BDNF levels as a neurodevelopmental marker in humans.

Neurodevelopment is a dynamic process that involves neurogenesis, neuronal migration, cortical growth and gyrification, starting in early pregnancy and lasting until infancy (first 1000 days). The pre- and periconceptional period is an important window within this broader window because of ‘epigenetic reprogramming’ of the conceptus which happens within 48-72 hours of conception(44). The majority of pregnancies are unplanned, and women approach the healthcare system after this window. Our supplementation was specifically started in adolescence to ensure adequate micronutrient stores in the mother from before conception, in time to support gametogenesis, conception, embryogenesis, organogenesis, and placentation. (43,45). The success of pre-conceptional folic acid supplementation in preventing NTDs is well known (23–25). Thus, we propose that the 1000-day window should be expanded to include the preconception period. This would shift the action from the clinic to the community and will fit well into a multitude of adolescent and reproductive age programs across the world.

Additional strengths of the PRIYA is that it is a trial within a cohort in which original observations were made. The randomized controlled trial design ensured that potential confounders were similarly distributed between allocation groups. High rates of participation in the trial, high rates of follow up, and of sample collection at delivery are also noteworthy. Exclusion of women with severe B12 deficiency (<100pM) from a placebo-controlled trial on ethical grounds reduced the power of the study because they and their offspring could have benefited the most from the B12 supplementation. The COVID pandemic also interfered with our ability to test more children for neurodevelopment and meant that we missed the children of women who became pregnant later. Despite these limitations we were able to see the beneficial effects of the supplementation. We expect that the performance on the Bayley’s scale will reflect in neurodevelopmental indices at a later age.This will be tested during subsequent follow ups.

**5.0 Summary and Conclusion**

We found that pre-conceptional maternal supplementation with a near RDA dose (2 μg/day) of vitamin B12 exposed their offspring to higher vitamin B12 status peri-conceptionally and during pregnancy. This was associated with better neurodevelopmental performance in the children, in cognitive and language domains, between 24-42 months of age. Our study highlights an important role for maternal vitamin B12 in offspring neurodevelopment. We urge that the first 1000 days window be extended to include the pre-conceptional period. Our findings have strong implications for public health policy to improve the vitamin B12 status of young adolescents and reproductive age women in populations with a sizable prevalence of vitamin B12 deficiency. Utility of this approach in non-vegetarian populations, needs to be documented. We foresee benefits of such a policy to many national nutrition programmes in India.

**Figure 1** **Consort diagram depicting the recruitment of study participants**

**Figure 2** **Bar graph comparing scores in BSID-III domains between treatment and placebo groups**

**Authors contributor statement**

CSY and RVB designed the neurocognitive follow-up study. ND and RVB analysed the data and wrote the first draft. BP and MD performed and reported the neurocognitive assessments. DB performed the biochemical measurements. AB contributed to the statistical analysis. SS and RS conducted the follow-up of the participants. KK, RL, and PY contributed to conducting the PRIYA trial. CSY and CF designed the original PRIYA trial. CSY and CF edited the final manuscript. All authors contributed to the article and approved the submitted version.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Acknowledgments**

We are grateful to the participants of the PMNS for their cooperation in this trial. We acknowledge the contribution of the field workers - Mr Ankush Bhalerao, Mr Suresh Chougule, Mr Vishnu Solat and Ms Rajani Bendge, Ms Malti Raut, Ms Mangal Gaikwad, Ms Sujata Jagtap, Ms Sarla Bagate, Ms Jayshri Kalokhe in conducting the trial. We thank Ms Anagha Deshmukh, Ms Sarah Khan, Ms Deepa Raut, Ms Sayali Wadke, Ms Rajashree Kamat for their assistance in data collection.

**Funding**

The PRIYA trial is funded by the Indian Council of Medical Research (58/1/8/

MRC-ICMR/2009/NCD-II) and Medical Research Council, UK (MR/J000094/1) as

part of an Indo-UK collaborative call.

The biological sample collection and analysis was funded by the DBT-CEIB grant BT/PR12629/MED/97/364/2016

The neurocognitive follow up and cord BDNF measurements was supported by the DBT/Wellcome India Alliance Fellowship [IA/CPHI/161502665] awarded to RB.

CSY was visiting professor at Danish Diabetes Academy & Southern University of Denmark (2016-2018) which was funded by NOVO-NORDISK FONDEN.

**References**

1. Lucas A. Programming by early nutrition in man. Ciba Found Symp. 1991;156:38–50; discussion 50-55.

2. Barker DJP. The origins of the developmental origins theory. J Intern Med. 2007 May;261(5):412–7.

3. Cusick SE, Georgieff MK. The Role of Nutrition in Brain Development: The Golden Opportunity of the “First 1000 Days.” J Pediatr. 2016 Aug;175:16–21.

4. Kalhan SC. One carbon metabolism in pregnancy: Impact on maternal, fetal and neonatal health. Mol Cell Endocrinol. 2016 Nov;435:48–60.

5. Godbole K, Gayathri P, Ghule S, Sasirekha BV, Kanitkar-Damle A, Memane N, et al. Maternal one-carbon metabolism, MTHFR and TCN2 genotypes and neural tube defects in India. Birt Defects Res A Clin Mol Teratol. 2011 Sep;91(9):848–56.

6. Suren P, Roth C, Bresnahan M, Haugen M, Hornig M, Hirtz D, et al. Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. JAMA. 2013;309–6.

7. Ars CL, Nijs IM, Marroun HE, Muetzel R, Schmidt M, Steenweg-de Graaff J, et al. Prenatal folate, homocysteine and vitamin B12 levels and child brain volumes, cognitive development and psychological functioning: the Generation R Study. Br J Nutr. 2016 Jan 22;1–9.

8. Schlotz W, Phillips DI. Fetal origins of mental health: evidence and mechanisms. Brain Behav Immun. 2009;23(7):905–16.

9. Sable P, Dangat K, Kale A, Joshi S. Altered brain neurotrophins at birth: consequence of imbalance in maternal folic acid and vitamin B12 metabolism. Neuroscience. 2011 Sep;190:127–34.

10. Sable PS, Kale AA, Joshi SR. Prenatal omega 3 fatty acid supplementation to a micronutrient imbalanced diet protects brain neurotrophins in both the cortex and hippocampus in the adult rat offspring. Metabolism. 2013 Nov;62(11):1607–22.

11. Yajnik CS, Deshpande SS, Jackson AA, Refsum H, Rao S, Fisher DJ, et al. Vitamin B12 and folate concentrations during pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study. Diabetologia. 2007 Nov 29;51(1):29–38.

12. Finkelstein JL, Kurpad AV, Thomas T, Srinivasan K, Duggan C. Vitamin B12 status in pregnant women and their infants in South India. Eur J Clin Nutr. 2017;71(9):1046–53.

13. Chanarin I, O’Hea A-M, Malkowska V, Rinsler MG, Price AB. MEGALOBLASTIC ANAEMIA IN A VEGETARIAN HINDU COMMUNITY. The Lancet. 1985 Nov;326(8465):1168–72.

14. Price SR. Observations on dietary practices in India. Hum Nutr Appl Nutr. 1984 Oct;38(5):383–9.

15. Jathar VS, Inamdar-Deshmukh AB, Rege DV, Satoskar RS. Vitamin B12 and Vegetarianism in India. Acta Haematol. 1975;53(2):90–7.

16. Yajnik CS, Deshpande SS, Lubree HG, Naik SS, Bhat DS, Uradey BS, et al. Vitamin B12 deficiency and hyperhomocysteinemia in rural and urban Indians. J Assoc Physicians India. 2006 Oct;54:775–82.

17. Behere RV, Deshmukh AS, Otiv S, Gupte MD, Yajnik CS. Maternal Vitamin B12 Status During Pregnancy and Its Association With Outcomes of Pregnancy and Health of the Offspring: A Systematic Review and Implications for Policy in India. Front Endocrinol. 2021 Apr 12;12:619176.

18. Bhate V, Deshpande S, Bhat D, Joshi N, Ladkat R, Watve S, et al. Vitamin B 12 Status of Pregnant Indian Women and Cognitive Function in their 9-year-old Children. Food Nutr Bull. 2008 Dec;29(4):249–54.

19. Bhate VK, Joshi SM, Ladkat RS, Deshmukh US, Lubree HG, Katre PA, et al. Vitamin B12 and folate during pregnancy and offspring motor, mental and social development at 2 years of age. J Dev Orig Health Dis. 2012 Apr;3(2):123–30.

20. Duggan C, Srinivasan K, Thomas T, Samuel T, Rajendran R, Muthayya S, et al. Vitamin B-12 Supplementation during Pregnancy and Early Lactation Increases Maternal, Breast Milk, and Infant Measures of Vitamin B-12 Status. J Nutr. 2014 May 1;144(5):758–64.

21. Thomas S, Thomas T, Bosch RJ, Ramthal A, Bellinger DC, Kurpad AV, et al. Effect of Maternal Vitamin B12 Supplementation on Cognitive Outcomes in South Indian Children: A Randomized Controlled Clinical Trial. Matern Child Health J. 2019 Feb;23(2):155–63.

22. Greene NDE, Copp AJ. Neural Tube Defects. Annu Rev Neurosci. 2014 Jul 8;37(1):221–42.

23. Wald N, Sneddon J, Densem J, Frost C, Stone R. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338(8760):131–7.

24. Czeizel AE, Dobó M, Vargha P. Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities. Birt Defects Res A Clin Mol Teratol. 2004 Nov;70(11):853–61.

25. Central Technical Co-ordinating Unit, ICMRCentral Technical Co-ordinating Unit, ICMR. Multicentric study of efficacy of periconceptional folic acid containing vitamin supplementation in prevention of open neural tube defects from India. Indian J Med Res. 2000 Dec;112:206–11.

26. Kumaran K, Yajnik P, Lubree H, Joglekar C, Bhat D, Katre P, et al. The Pune Rural Intervention in Young Adolescents (PRIYA) study: design and methods of a randomised controlled trial. BMC Nutr [Internet]. 2017 Dec [cited 2019 Jan 22];3(1). Available from: http://bmcnutr.biomedcentral.com/articles/10.1186/s40795-017-0143-5

27. Bayley N. Bayley Scales of Infant and Toddler Development: Bayley-III. Harcourt Assessment, Psych.Corporation; 2006.

28. Strand TA, Taneja S, Ueland PM, Refsum H, Bahl R, Schneede J, et al. Cobalamin and folate status predicts mental development scores in North Indian children 12-18 mo of age. Am J Clin Nutr. 2013 Feb;97(2):310–7.

29. Veena SR, Krishnaveni GV, Srinivasan K, Wills AK, Muthayya S, Kurpad AV, et al. Higher maternal plasma folate but not vitamin B-12 concentrations during pregnancy are associated with better cognitive function scores in 9- to 10- year-old children in South India. J Nutr. 2010 May;140(5):1014–22.

30. Veena SR, Gale CR, Krishnaveni GV, Kehoe SH, Srinivasan K, Fall CH. Association between maternal nutritional status in pregnancy and offspring cognitive function during childhood and adolescence; a systematic review. BMC Pregnancy Childbirth. 2016 Dec;16(1):220.

31. del Río Garcia C, Torres-Sánchez L, Chen J, Schnaas L, Hernández C, Osorio E, et al. Maternal *MTHFR 677C>T* genotype and dietary intake of folate and vitamin B 12 : their impact on child neurodevelopment. Nutr Neurosci. 2009 Feb;12(1):13–20.

32. Lai JS, Mohamad Ayob MN, Cai S, Quah PL, Gluckman PD, Shek LP, et al. Maternal plasma vitamin B12 concentrations during pregnancy and infant cognitive outcomes at 2 years of age. Br J Nutr. 2019 Jun;121(11):1303–12.

33. Bonilla C, Lawlor DA, Ben-Shlomo Y, Ness AR, Gunnell D, Ring SM, et al. Maternal and offspring fasting glucose and type 2 diabetes-associated genetic variants and cognitive function at age 8: a Mendelian randomization study in the Avon Longitudinal Study of Parents and Children. BMC Med Genet. 2012 Sep 27;13:90.

34. Wu BTF, Dyer RA, King DJ, Richardson KJ, Innis SM. Early Second Trimester Maternal Plasma Choline and Betaine Are Related to Measures of Early Cognitive Development in Term Infants. Szecsi PB, editor. PLoS ONE. 2012 Aug 20;7(8):e43448.

35. Kvestad I, Taneja S, Kumar T, Hysing M, Refsum H, Yajnik CS, et al. Vitamin B12 and Folic Acid Improve Gross Motor and Problem-Solving Skills in Young North Indian Children: A Randomized Placebo-Controlled Trial. Cameron DW, editor. PLOS ONE. 2015 Jun 22;10(6):e0129915.

36. Bhat DS, Thuse NV, Lubree HG, Joglekar CV, Naik SS, Ramdas LV, et al. Increases in plasma holotranscobalamin can be used to assess vitamin B-12 absorption in individuals with low plasma vitamin B-12. J Nutr. 2009 Nov;139(11):2119–23.

37. Deshmukh US, Joglekar CV, Lubree HG, Ramdas LV, Bhat DS, Naik SS, et al. Effect of physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-controlled, double-blind trial in India. Eur J Clin Nutr. 2010 May;64(5):495–502.

38. Yajnik CS, Behere RV, Bhat DS, Memane N, Raut D, Ladkat R, et al. A physiological dose of oral vitamin B-12 improves hematological, biochemical-metabolic indices and peripheral nerve function in B-12 deficient Indian adolescent women. Loor JJ, editor. PLOS ONE. 2019 Oct 10;14(10):e0223000.

39. Yajnik C, Kasture S, Kantikar V, Lubree H, Bhat D, Raut D, et al. Efficacy of B 12 Fortified Nutrient Bar and Yogurt in Improving Plasma B12 Concentrations—Results From 2 Double-Blind Randomized Placebo Controlled Trials. Food Nutr Bull. 2021 Jun 30;037957212110254.

40. Sandström B. Micronutrient interactions: effects on absorption and bioavailability. Br J Nutr. 2001 May;85 Suppl 2:S181-185.

41. Devakumar D, Fall CHD, Sachdev HS, Margetts BM, Osmond C, Wells JCK, et al. Maternal antenatal multiple micronutrient supplementation for long-term health benefits in children: a systematic review and meta-analysis. BMC Med. 2016 Jun 16;14:90.

42. Green R, Allen LH, Bjørke-Monsen A-L, Brito A, Guéant J-L, Miller JW, et al. Vitamin B12 deficiency. Nat Rev Dis Primer. 2017 Dec 21;3(1):17040.

43. Fleming TP, Watkins AJ, Velazquez MA, Mathers JC, Prentice AM, Stephenson J, et al. Origins of lifetime health around the time of conception: causes and consequences. Lancet Lond Engl. 2018 May 5;391(10132):1842–52.

44. Amoako AA, Nafee TM, Ola B. Epigenetic Influences During the Periconception Period and Assisted Reproduction. In: Fazeli A, Holt WV, editors. Periconception in Physiology and Medicine [Internet]. Cham: Springer International Publishing; 2017 [cited 2021 Jul 14]. p. 15–39. (Advances in Experimental Medicine and Biology; vol. 1014). Available from: http://link.springer.com/10.1007/978-3-319-62414-3\_2

45. Steegers-Theunissen RPM, Twigt J, Pestinger V, Sinclair KD. The periconceptional period, reproduction and long-term health of offspring: the importance of one-carbon metabolism. Hum Reprod Update. 2013 Nov 1;19(6):640–55.

**Table 1.** Maternal characteristics at baseline and in pregnancy, and child characteristics

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Variables** |  **n#** | **Placebo Group**  | **n** | **B12+MMN Group**  | **n** | **B12 Group** | **p values** |
| **Parental sociodemographic characteristics** |
| Maternal age at 28 weeks gestation (years) | 25 | 19.8 (1.0) | 25 | 19.4 (1.1) | 21 | 19.7 (1.1) | 0.555 |
| Maternal education (years) | 26 | 12.5 (11.0,13.0) | 26 | 12.0 (10.0, 13.0) | 21 | 12.0 (11.0, 13.5) | 0.639 |
| Maternal height (cms) | 25 | 158.2 (5.2) | 25 | 158.7 (5.0) | 21 | 157.8 (4.8) | 0.852 |
| Maternal weight at 28 weeks gestation (kgs) | 25 | 55.4 (48.6, 59.3) | 25 | 51.2 (49.4, 54.4) | 21 | 52.9 (47.0, 60.7) | 0.656 |
| Maternal IQ  | 21 | 76.6 (9.5) | 15 | 74.4 (8.8) | 17 | 75.8 (7.2) | 0.751 |
| Standard of Living Index | 26 | 36.0 (30.5, 40.5) | 26 | 38.0 (31.0, 40.0) | 21 | 37.0 (32.0, 40.0) | 0.923 |
| Paternal Education (years) | 25 | 14.0 (10.5, 15.0) | 24 | 12.0 (10.0, 15.0) | 19 | 12.0 (10.0, 15.0) | 0.656 |
| Duration of supplementation (months) | 27 | 34.0 (22.0, 45.0) | 26 | 36.0 (21.0, 45.2) | 21 | 35.0 (23.0, 49.5) | 0.937 |
| Compliance (percentage)  | 27 | 89.4 (76.0, 94.8) | 26 | 77.5 (67.8, 88.5) | 21 | 81.5 (72.3, 87.8) | 0.649 |
|  **Maternal Micronutrients**  | **p values****(B12+MMN vs Placebo)** | **p values****(B12 vs Placebo)** |
| **At screening**  |
| Vitamin B12 (pM) | 27 | 151.0 (122.0, 193.0) | 26 | 159.5 (134.0, 219.0) | 21 | 138.0 (125.0,190.0) | 0.350 | 0.860 |
| Holo-TC | 27 | 11.0 (8.3, 13.4) | 26 | 11.1 (6.2, 15.8) | 21 | 7.9 (5.3, 11.4) | 0.87 | 0.30 |
| Folate (nM)  | 27 | 20.9 (15.3, 24.6) | 26 | 15.7 (11.3, 26.6) | 21 | 20.8 (15.3, 29.1) | 0.357 | 0.698 |
| Homocysteine (µmol/L) | 27 | 20.1 (15.1, 38.0) | 26 | 18.6 (15.3, 30.3) | 21 | 27.5 (17.0, 39.6) | 0.646 | 0.434 |
| **At 18 years** |
| Vitamin B12 (pM) | 25 | 162.0 (125.9, 192.5) | 26 | 285.0 (205.8, 368.7) | 18 | 274.7 (224.7, 388.2) | <0.001\*\*\* | <0.001\*\*\* |
| Holo-TC | 27 | 9.5 (6.2, 14.9) | 26 | 22.6 (8.7, 29.2) | 19 | 25.2 (8.1, 36.0) | <0.001\*\*\* | <0.001\*\*\* |
| Folate (nM) | 26 | 23.0 (17.2, 29.8) | 26 | 21.2 (15.3, 28.8) | 18 | 20.4 (14.9, 28.3) | 0.734 | 0.925 |
| Homocysteine (µmol/L)  | 27 | 16.7 (11.7, 28.3) | 26 | 9.60 (8.30, 13.4) | 18 | 10.6 (9.22, 16.0) | <0.001\*\*\* | 0.013\* |
| **At 28 weeks gestation** |
| Hemoglobin (gm/dl) | 25 | 10.4 (9.5, 11.0) | 25 | 10.2 (9.4, 11.0) | 21 | 10.4 (9.1, 10.7) | 0.491 | 0.638 |
| Vitamin B12 (pM) | 25 | 134.0 (95.5, 163.0) | 25 | 164.0 (149.0, 218.5) | 21 | 204.0 (173.5, 261.0) | 0.007\*\* | <0.001\*\*\* |
| Holo-TC (pM) | 25 | 14.8 (8.85, 25.1) | 25 | 21.9 (15.3, 36.5) | 21 | 21.3 (16.9, 36.8) | 0.027\* | 0.012\* |
| Folate (nM) | 25 | 47.9 (18.0, 71.5) | 25 | 20.6 (10.2, 49.7) | 21 | 28.5 (16.6, 51.4) | 0.043\* | 0.302 |
| Vitamin B2 (pM) | 25 | 244.0 (210.5, 273.0) | 25 | 276.0 (229.5, 304.5) | 20 | 244.0 (221.7, 269.5) | 0.028\* | 0.852 |
| Viamin B6-pyridoxal-5-phospate (pM) | 24 | 3.5 (2.3, 4.6) | 25 | 4.6 (3.3, 7.4) | 21 | 3.1 (2.6, 4.8) | 0.117 | 0.357 |
| Vitamin B6-pyridoxal (pM) | 15 | 1.0 (0.8, 1.6) | 12 | 1.1 (0.9, 1.3) | 12 | 1.3 (1.0, 1.7) | 0.786 | 0.922 |
| Homocysteine (µmol/L) | 25 | 7.0 (5.0, 9.2) | 25 | 6.3 (4.3, 8.1) | 21 |  5.1 (3.9, 7.2)  | 0.559 | 0.550 |
| **Child Characteristics** |
| Child age at assessment (months) | 27 | 27 (26, 34) | 26 | 29 (27, 36.2) | 21 | 29 (26, 32) | 0.623 | 0.901 |
| Gender | 27 | Boys=18 (66.7%) | 26 | Boys=13 (50%) | 21 | Boys=11 (52.3%) |  |  |
| **Birth Anthropometry** |
| Gestation age (weeks) | 27 | 39.0 (38.0, 40.2) | 26 | 39.0 (38.0, 40.2) | 21 | 39.4 (38.8, 40.2) | 0.920 | 0.936 |
| Birth weight (gm) | 27 | 2908.6 (412.5) | 26 | 2809.2 (458.6) | 21 | 2788.9 (315.9) | 0.411 | 0.277 |
| Birth length (cm) | 27 | 49.1 (46.8, 49.8) | 26 | 48.2 (47.4, 49.8) | 20 | 48.5 (47.2, 49.3) | 0.990  | 0.328 |
| Head circumference (cm) | 27 | 33.4 (1.0) | 26 | 33.1 (1.0) | 20 | 33.0 (0.9) | 0.237 | 0.142 |
| **Cord Micronutrients** |
| Vitamin B12 (pM) | 27 | 226.0 (138.0, 289.0) | 26 | 275.5 (181.7, 313.7) | 21 | 289.0 (167.0, 446.0) | 0.240 | 0.200 |
| Holo-TC (pM) | 27 | 40.7 (23.3, 81.9) | 26 | 79.4 (39.2, 125.0) | 21 | 96.1 (39.4, 125.0) | 0.021\* | 0.048\* |
| Folate (nM) | 27 | 55.9 (37.9, 70.8) | 26 | 52.0 (36.8, 68.1) | 21 | 42.7 (31.3, 80.0) | 0.473 | 0.278 |
| Vitamin B2 (pM) | 26 | 357 (73.7) | 25 | 316 (73.5) | 20 | 314 (67.3) | 0.053 | 0.924 |
| Vitamin B6-pyridoxal-5-phospate (pM) | 12 | 29.3 (18.6, 42.7) | 13 | 25.0 (19.1, 39.5) | 13 | 17.5 (11.6, 43.9) | 0.494 | 0.298 |
| Vitamin B6-pyridoxal (pM) | 26 | 4.80 (3.6, 7.9) | 25 | 5.70 (4.6, 8.3) | 21 | 4.80 (3.2, 6.9) | 0.187 | 0.806 |
| Homocysteine (µmol/L) | 27 | 8.30 (6.8, 11.6) | 26 | 6.30 (4.8, 9.8) | 21 | 6.60 (4.6, 11.9) | 0.134 | 0.342 |
| BDNF (pg/ml) | 27 | 70.0 (31.0, 299.0) | 26 | 106.0 (31.0, 412.2) | 21 | 195.0 (31.0, 512.0) | 0.620 | 0.364 |

Values represented as Mean (SD), Median (25th, 75th) or n (%)

\*p<0.05, \*\*p<0.01 \*\*\*p<0.001 p-values calculated by t-test

IQ, Intelligence Quotient; Holo-TC, holotranscobalamin; BDNF, Brain Derived Neurotrophic Factor; MMN, multi micronutrient

#The number of women attending the follow up differed across the three time points.

**Table 2.** Comparison between placebo and supplemented groups in BSID-III domains

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **BSID-III domains** | **Placebo Group** | **B12+MMN Group** | **B12 Group** | **#p value** | **$p value** |
| **Group (B12+MMN** **vs Placebo)** | **Group****(B12** **vs Placebo)** | **Group (B12+MMN vs Placebo)** | **Group** **(B12** **vs Placebo)** |
| **Cognitive** | 90.0 (85.0, 95.0) | 90.0 (85.0, 96.2) | 95.0 (90.0, 100) | 0.969 | 0.034\* | 0.781 | 0.044\* |
| **Motor** | 94.0 (91.0, 100.0) | 95.5 (90.2, 100.0) | 97.0 (91.0, 107.0) | 0.687 | 0.818 | 0.522 | 0.384 |
| **Language** | 92.2 (7.8) | 93.7 (9.87) | 98.6 (10.1) | 0.556 | 0.020\* | 0.633 | 0.020\* |

Values represented as Mean (SD) or Median (25th, 75th)

\*p<0.05

#P value calculated by t test

$P value calculated by ANCOVA; adjusted for maternal baseline B12 levels

Language performance was normally distributed, and Mean (SD) are reported

MMN, multi micronutrient